Acetanilide

Summary

Acetanilide (CHEMBL269644) is an approved small-molecule analgesic.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 135.16 Da · C8H9NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL269644
Name	Acetanilide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	904
ChEBI	CHEBI:28884
Molecular formula	C8H9NO
Molecular weight	135.16
InChIKey	FZERHIULMFGESH-UHFFFAOYSA-N

SMILES: CC(=O)NC1=CC=CC=C1

IUPAC name: N-phenylacetamide

ChEBI definition: A member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen is substituted by a phenyl group.

Pharmacological roles (ChEBI): analgesic.

Also known as: Acetaminophen related compound d, Acetanilid, Acetanilide, Acetanilidum, Antifebrin, Antifebrinum, NSC-203231, NSC-7636, Phenalgene, N-Phenyl-acetamide, N-Phenyl-acetamide; Acetanilide, Acetoanilide

Parent form; salt/anhydrous children: CHEMBL3349336

Patent coverage: 9,877 distinct patent families (23,640 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 3-hydroxyacyl-CoA dehydrogenase type-2, Nicotinate phosphoribosyltransferase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NAPRT	9	Ki	1	nM	CHEMBL_ACT_19323239

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).